Medarex/Bristol Plan To File Ipilimumab For Metastatic Melanoma Despite Phase II Failure
Totality of the data, clear dose response and limited treatment options in this patient population justify regulatory approval, firms maintain.
Totality of the data, clear dose response and limited treatment options in this patient population justify regulatory approval, firms maintain.